

Due to the current respiratory syncytial virus (RSV) levels in Oklahoma, SoonerCare is not currently covering Synagis (palivizumab). The Oklahoma Health Care Authority (OHCA) will continue to monitor RSV levels in Oklahoma for further coverage consideration. The Synagis prior authorization (PA) forms will be posted to the OHCA website prior to the start of coverage.

Please note: Palivizumab is approved for use only during RSV season in Oklahoma as determined by the Oklahoma State Department of Health (OSDH) Viral Respiratory Illness Sentinel Surveillance System or other credible statewide monitoring system. The threshold for determining RSV seasonality is 10% of positive tests. RSV is determined to be in season once the percentage of positive tests is >10% for 2 consecutive weeks; however, due to a potential lag in reporting data, palivizumab coverage may begin when the percentage of positive tests is consistently increasing and approaching the 10% threshold. RSV season is determined to be at an end when the percentage of positive tests is consistently <10%.

Updated 02/09/2023